Carfilzomib (Kyprolis): A novel proteasome inhibitor for relapsed and/or refractory multiple myeloma

P and T

Volumn 41, Issue 5, 2016, Pages 303-307

  Perel, Galina ^a   Bliss, Joshua ^b   Thomas, Christan M ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; LENALIDOMIDE; PROTEASOME;

ACUTE KIDNEY FAILURE; ANEMIA; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FEVER; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; LACTATION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; NOTE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84966599688     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Kuehl MW, Bergsagel LP. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122;(10):3456-3463.
2. van Rhee F, Anaissie E, Angtuaco E, et al. Chapter 109: Myeloma. In: Lichtman MA, Kipps TJ, Seligsohn U, et al. Williams Hematology 8th edNew York, New York: McGraw-Hill. 2010;
3. National Cancer Institute, Surveillance Epidemiology, and End Results Program. SEER cancer statistics review, 1975-2006. Available at:http://seer.cancer.gov/csr/1975_2006/results_merged/sect_18_myeloma.pdf. Accessed November 2, 2015.
4. Kyprolis (carfilozomib) prescribing information Thousand Oaks, California: Amgen. January 2016;
5. Food and Drug Administration. Carfilzomib July 202012;Available at:www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm312945.htm. Accessed March 4, 2016.
6. Food and Drug Administration. Carfilzomib/Kyprolis. July242015;www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455873.htm. Accessed March 4, 2016.
7. Carfilzomib. Lexi-Drugs Online Hudson, Ohio: Lexi-Comp, Inc. Updated October 19, 2015. Available at: http://online.lexi.com. Accessed November 2, 2015.
8. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47.
9. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013;121;(6):893-897.10.1182/blood-2012-10-459883
10. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120;(14):2817-2825.10.1182/blood-2012-05-425934
11. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med 2015;372;(2):142-152.10.1056/NEJMoa1411321
12. Arraras Urdaniz JI, Vera García R, Martínez Aguillo M, et al. Quality of Life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages. Clin Transl Oncol2006;8;(9):664-671.
13. Red Book Online Ann Arbor, Michigan: Truven Health Analytics. Accessed April 8, 2016.